Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34237250

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Aug
First author
Brose MS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Brose MS
      type
      Author
    2. name
      Robinson B
      type
      Author
    3. name
      Sherman SI
      type
      Author
    4. name
      Krajewska J
      type
      Author
    5. name
      Lin CC
      type
      Author
    6. name
      Vaisman F
      type
      Author
    7. name
      Hoff AO
      type
      Author
    8. name
      Hitre E
      type
      Author
    9. name
      Bowles DW
      type
      Author
    10. name
      Hernando J
      type
      Author
    11. name
      Faoro L
      type
      Author
    12. name
      Banerjee K
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Brose MS
      type
      Author
    2. name
      Robinson B
      type
      Author
    3. name
      Sherman SI
      type
      Author
    4. name
      Krajewska J
      type
      Author
    5. name
      Lin CC
      type
      Author
    6. name
      Vaisman F
      type
      Author
    7. name
      Hoff AO
      type
      Author
    8. name
      Hitre E
      type
      Author
    9. name
      Bowles DW
      type
      Author
    10. name
      Hernando J
      type
      Author
    11. name
      Faoro L
      type
      Author
    12. name
      Banerjee K
      type
      Author
    bibliography ids
    1. nci-bib-e0f5e174f02aaa03e9b3bf32
    book metadata
    content sha256
    0330865c5bc28465ae23f1c191834cb6eeca662f81a2d17c045f2ec52970590e
    document type
    citation
    dois
    1. 10.1016/S1470-2045(21)00332-6
    electronic publication date
    display
    2021 Jul 5
    precision
    day
    year
    2021
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:34237250
    immutable id
    pubmed:34237250@0330865c5bc28465ae23f1c191834cb6eeca662f81a2d17c045f2ec52970590e
    journal
    abbreviation
    Lancet Oncol
    issn electronic
    1474-5488
    issn print
    1470-2045
    issue
    8
    name
    The Lancet. Oncology
    nlm unique id
    100957246
    pages
    1126-1138
    volume
    22
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      34237250
      provenance
      batch id
      192b6392c165c6b06274
      provider
      NCBI PubMed ESummary
      record sha256
      1dffe9e6b016b1a17452df8840e03117a5dc1a84e452a4104fef12387131427f
      response sha256
      7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
      retrieved at
      2026-09-09T23:48:02.713075+00:00
      publication date
      display
      2021 Aug
      precision
      month
      year
      2021
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      5. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/34237250/
      title
      Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.

      Preserved source evidence · Not medical advice